Ascletis Pharma Inc. (HKEX: 1672), a China-based R&D driven biotech company, announced on Monday that it has received the Investigational New Drug (IND) application approval from United States Food and Drug Administration (FDA) and started global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for the functional cure of chronic hepatitis B.
The product has undergone the ASC22 Phase IIb study (ClinicalTrials.gov Identifier: NCT04465890), a randomised, single-blind, placebo-controlled, multi-centre clinical trial in China that assessed the efficiency and safety of 149 chronic hepatitis B patients for 24-week treatment of 1mg/kg or 2.5mg/kg ASC22 or matching placebo offered once every two weeks along with NAs.
Ascletis Pharma Inc has received a global and exclusive license effective 8 November 2021 from Suzhou Alphamab to develop and commercialise ASC22 for all viral diseases including Hepatitis B.
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes